,,,hummmm,,,, I would like to see the team come up with a different solution to their continual cash crunch issues,,,,,,,,why not sell the patents on some of their molecules in a fair arrangement to a partner/s,,,,,,if they cant find a buyer for the company at their price then sell part of their pipeline,,,,,,,,,,,,,allow a deep pocketed entitiy to do some of the slug and tug in the clinic and perhaps get at least one epigenetic drug to market.

I think DMcC and gang are tooo greedy with this technology,,,,it may be time the team realizes a new avenue of approach is required. These large insiders have no choice but to hang onto their shares most likely cuz they wouldnt be able to find a buyer at present,,,so its the data data data they are crossing their fingers for come Nov. 16th as well,,,,,,,,no matter,,,,,we need a new approach to get our epigenetic pipeline into clinical trials.

Is it not possible that by having limited funds the design of this BoM trial was tailered on the cheapo side??...which might have been a cause of the miss with TLD. Either way our molecules are many years away from the counter if we keep our present business model in research and no development,,,,,jmo

Buckeyes,,,,,,,,,yeaa,,,,,,,,maybe incineration of a nice fat reefer would be just what DMcC needs to have a good deep think here,,,,,, I will volunteer to assist if need be!!! hahhaha!!